Meril Life Sciences Joins Hands with Japan Lifeline to Promote Heart Valve

The cardiovascular solution features a wide range of sizes to fit a broader patient population as compared to legacy technology. It also has a unique octagonal cell structure that improves accuracy of placement.

Gujarat-based medical devices maker Meril Life Sciences has signed an agreement with Japan’s cardiovascular medtech company Japan Lifeline to promote Meril’s transcathether heart valve.

This strategic alliance grants Japan Lifeline exclusive rights to promote Meril’s transcatheter heart valve, Myval Octacor upon PMDA approval in Japan.

Myval Octacor is a balloon-expandable transcatheter heart valve implant designed for transcatheter aortic valve replacement or implantation (TAVR/ TAVI) procedures.

Further, the cardiovascular solution features a wide range of sizes to fit a broader patient population as compared to legacy technology. It also has a unique octagonal cell structure that improves accuracy of placement.

Sharing his views, Sanjeev Bhatt, senior VP, corporate strategy, Meril Life Sciences said, "Our collaboration with Japan Lifeline represents a pivotal moment for Meril. We are confident that our partnership will not only enhance patient outcomes but also strengthen our position as a global leader in cardiovascular solutions."

Founded in 2006, Meril Life Sciences is an India-based global medical device company. It is part of the Bilakhia Group. The company operates in various medical fields, including vascular intervention devices, orthopedic implants, endosurgery, ENT products, and in-vitro diagnostics.

Over the past seven years, Meril has produced more than 25,000 heart valves that have been implanted in patients across 75 countries with clinical safety, and efficacy that is supported by 80+ scientific publications.

Commenting on the partnership, Keisuke Suzuki, president and CEO, Japan Lifeline, said, "We have been involved in the field of heart valve disease treatment for about 30 years. It's very emotional for us to enter the market with a next-generation TAVR TAVI technology that has proven clinical results worldwide."

Japan Lifeline Co, Ltd, on the other hand, was established in 1981. The Japan-based company is involved in the import, development, production, and distribution of medical devices. It aims to contribute to the betterment of society by importing, developing, producing, and distributing high-quality medical devices.

In a similar development, NHCS and Novoheart collaborated to develop the world's first Asian patient-specific miniature human heart model. Leveraging Novoheart's proprietary bioengineering technologies, the collaboration aims to craft the inaugural Asian patient-specific mini-heart models capable of replicating key features observed in individuals with heart failure with preserved ejection fraction (HFpEF).

The strategic partnership between NHCS and Novoheart holds the promise of advancing care for HFpEF patients. The bioengineering of the Asian patient-specific HFpEF mini-heart model, the "Human Heart-in-a-Jar," is a pioneering initiative in Asia.